Because the primarily localization of RanGAP1 in the cytoplasm and at the NPC is required for efficient nuclear transport especially in cancer cells, targeting CRM1 with small-molecule inhibitors in certain types of cancers with overexpression of RanGAP1 and/or CRM1 might be a promising strategy for therapeutic treatment of these diseases. Here, XPO1 is linked to cancer.